Emcure Pharmaceuticals saw its international business emerge as the primary growth engine in FY26, with sales rising 22.2% YoY to ₹5,177 crore.
The Europe segment recorded the fastest growth at 25.5%, followed by Emerging Markets at 21.8% and Canada at 18.7%.
Overall revenue from operations stood at ₹9,204 crore, up 16.6% YoY, while adjusted PAT rose 40.9% to ₹1,008 crore.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear – to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.”
